

What is claimed is:

1. Use of an anti-PD-L1 antibody or an antigen-binding fragment thereof, an anti-CTLA-4 antibody or an antigen-binding fragment thereof, and an OX40 agonist in the manufacture of a medicament for the treatment of a solid tumor in a subject, wherein the medicament is to be administered to the subject.
2. The use of claim 1, wherein the OX40 agonist is one or more of an OX40 ligand fusion protein or anti-OX40 antibody.
3. The use of claim 2, wherein the OX40 ligand fusion protein is MEDI6383.
4. The use of any one of claims 1-3, wherein the anti-PD-L1 antibody is MEDI4736.
5. The use of any one of claims 1-4, wherein the anti-CTLA-4 antibody is tremelimumab.
6. Use of MEDI4736 or an antigen-binding fragment thereof, tremelimumab or an antigen-binding fragment thereof, and MEDI6383 in the manufacture of a medicament for the treatment of a solid tumor in a subject, wherein the medicament is to be administered to the subject.
7. The use of any one of claims 1-6, wherein the medicament is to be administered by intravenous infusion.
8. The use of any one of claims 1-7, wherein the solid tumor is an ovarian cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, uterine cancer, testicular cancer, bladder cancer, head and neck cancer, melanoma, pancreatic cancer, renal cell carcinoma, or lung cancer.
9. The use of claim 8, wherein the solid tumor is triple negative breast cancer.
10. The use of claim 9, wherein the solid tumor is a non-small cell lung cancer.
11. The use of claim 10, wherein the solid tumor is squamous or non-squamous non-small cell lung cancer.
12. The use of any one of claims 1-11, wherein the subject is a human patient.

13. A pharmaceutical composition comprising an effective amount of an anti-PD-L1 antibody or an antigen-binding fragment thereof, an anti-CTLA-4 antibody or an antigen-binding fragment thereof, and an OX40 agonist and a pharmaceutically acceptable excipient.
14. The pharmaceutical composition of claim 13, wherein the OX40 agonist is MEDI6383.
15. The pharmaceutical composition of any one of claims 13-14, wherein the anti-PD-L1 antibody is MEDI4736.
16. The pharmaceutical composition of any one of claims 13-15, wherein the anti-CTLA-4 antibody is tremelimumab.
17. A pharmaceutical composition comprising an effective amount of MEDI4736 or an antigen-binding fragment thereof, tremelimumab or an antigen-binding fragment thereof, and MEDI6383 and a pharmaceutically acceptable excipient.